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R etinoblastoma is the most frequently occurring malignant eye tumor in childhood. 1 Current treatments include enucleation, external beam radiotherapy, cryotherapy, photocoagulation, and chemotherapy. 1 Although these methods achieve over 95% survival, there remains a need for better treatment alternatives to improve visual results and to avoid enucleation in hereditary retinoblastoma. [2] [3] [4] Therefore, the studies of new therapeutic strategies including immunotherapy are needed. One attractive concept already applied to other tumors is to modulate the immune system in a way that enables it to recognize and kill tumor cells. 5 Mononuclear cell infiltration is observed in primary retinoblastoma and has been suggested to play an important role in host defense. 6 Barez et al. 7 have shown that major histocompatibility (MHC) class I plays a critical role in antigen presentation, and upregulation of this molecule by IFN-␥ may increase the susceptibility of tumor cells to cytotoxic T cells. Moreover, several studies indicate the possibility that the expression of adhesion molecules such as intercellular adhesion molecule (ICAM)-1 and nerve-cell adhesion molecule (NCAM) on human Y-79 cells plays a role in the pathogenesis of human retinoblastoma and that these molecules are also involved in host susceptibility. 6, 8, 9 Effective protective immunity against tumor depends on the concordant activity of cytotoxic T cells, 10 and costimulation of T cells on a tumor has been shown to be essential for eliciting cell-mediated antitumor immunity. 11 Optimal T-cell recognition is based primarily on the presentation of an antigen compatible with MHC class I molecules, whereas secondary costimulatory molecules such as the B7 family and the tumor necrosis factor (TNF) receptor superfamily are necessary to initiate maximum stimulation. 11 In recent years, several studies have indicated that tumor cells are able to deliver antigenspecific signals to T lymphocytes 12 and that T-cell activation is the result of a balance between positive and negative signals. CD28, ICOS, 4-1BB, and CD40 are major positive costimulatory receptors, and interaction with the respective ligands on tumor cells is essential for T-cell activation [13] [14] [15] [16] [17] In contrast, CTLA-4 and B7H1 expressed on tumor cells inhibit T-cell activation. 18, 19 However, the costimulatory molecule expression patterns differ among tumor cells. Tumor-reactive cytotoxic T lymphocytes isolated from the peripheral blood of cancer patients exhibit limited anti-tumor response. 20 In contrast, persistence and progressive growth of tumors indicate that the immune system is not generally competent to control the malignancy. Most tumor cells express little or no costimulatory molecules, 21 but enforced expression of some molecules (e.g., CD80, B7H2, OX40L, and 4-1BBL) by gene transfer has resulted in enhanced antitumor responses and tumor rejection in different animal models. [22] [23] [24] The results of these studies have provided the groundwork for various clinical trials of gene therapy in cancer patients, 25, 26 and most clinical trials use irradiated tumor cells as vaccine for safety reasons. Although irradiation is known to increase the inherent immunogenicity of some tumor cells, 27, 28 the effects of irradiation on the expression of MHC molecules and costimulatory molecules in human retinoblastoma cells have not been reported. Therefore, we sought to determine the in vitro expression patterns of MHC and costimulatory molecules in the human retinoblas-toma cell line Y-79 under various conditions and clarified their functional roles in the immune system.
MATERIALS AND METHODS

Cells and Culture Conditions
A human retinoblastoma cell line, Y-79, originally characterized by Reid et al., 29 was obtained from ATCC (HTB-18; Rockville, MD). The cell line was maintained as a suspension culture at a concentration of 2.5 ϫ 10 5 /mL in RPMI 1640 medium containing 10% FCS, 10 mM HEPES, 2 mM glutamine, 0.1 mg/mL penicillin, and streptomycin, in 5% CO 2 /95% air at 37°C. The cells were incubated with medium alone or in the presence of IFN-␥ (500 U/mL), and/or irradiated with an X-irradiator (Gammacell 40 Exactor; MDS Nordion International, Inc., Ottawa, Ontario, Canada).
Monoclonal Antibodies and Reagents
FITC-conjugated anti-HLA-DR, -DP, and -DQ (TÜ 39, IgG2a) mAbs; PEconjugated anti-human HLA-ABC (G46-2.6, IgG1), HLA-DR (G46-6, IgG2a), HLA-DQ (TÜ 169, IgG2a), CD80 (L307.4, IgG1), CD86 (IT2.2, IgG2b), 4-1BBL (C65-485, IgG1), B7-H2 (2D3/B7-H2, IgG2b), ICAM-1 (HA58, IgG1), NCAM (NCAM16.2, IgG2b), LFA-2 (RPA-2,10, IgG1), CD95 (DX2, IgG1), CD95L (NOK-1, IgG1), CD14 (M5E2, IgG2a), CD16 (3G8, IgG1), and CD20 (2H7, IgG2b) mAbs; mouse IgG isotype control; and recombinant human IFN-␥ were purchased from BD PharMingen (San Diego, CA). FITC-conjugated anti-CD40 (5C3, IgG1); PE-conjugated and purified blocking anti-human B7H1 (MIH1, IgG1), PE-conjugated anti-human PD-1 (J116, IgG1), and B7-DC (MIH18, IgG1) mAbs; and agonistic anti-CD3 mAb (OKT3, IgG2a) were purchased from eBiosciences (San Diego, CA). PE-conjugated anti-OX40L (ANC10G1, IgG1) and recombinant human CD40L were purchased from Alexis Biochemicals (Carlsbad, CA).
Flow Cytometric Analysis
For the flow cytometry analysis of costimulatory expression on the human retinoblastoma cell line, cells were washed once in PBS and 10 6 cells were incubated with FITC-or PE-labeled mAbs. For OX40L staining, cells were incubated with the anti-OX40L monoclonal mAb, washed, and then incubated with PE-conjugated goat anti-mouse mAb. After washing with PBS twice, the stained cells (live-gated on the basis of forward and side scatter profiles and propidium iodide exclusion) were analyzed on a flow cytometer (FACSCalibur; BD Biosciences, Franklin Lakes, NJ). Data were processed using the accompanying software (CellQuest; BD Biosciences), and expressed as mean fluorescence intensity (MFI). 
RNA Extraction, cDNA Synthesis, and RT-PCR
Y-79 Stimulation via CD40
Human retinoblastoma cell line Y-79 was cultured for 48 hours in medium, with or without 500 U/mL IFN-␥ unless stated otherwise, and then washed twice with PBS. They were then stimulated for 24 hours with rhCD40L or isotyped control Ig or medium alone.
Chemokine Production
Cell culture supernatants were assessed for the human chemokines monocyte chemotactic protein (MCP-1), macrophage inflammatory protein ( 
T-Cell Proliferation Assay
Heparinized blood samples were obtained from healthy individuals, who provided informed consent in accordance with the Declaration of Helsinki, and peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. CD3 ϩ T cells were purified with microbeads on auto-MACS columns with a pan T-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. Purified CD3 ϩ T-cell populations contained Ͼ97% CD3 ϩ T cells and Ͻ1% CD14 ϩ , CD16 ϩ , and CD20 ϩ cells, as determined by flow cytometry. Purified CD3 ϩ T cells (3 ϫ 10 5 /well) were cocultured with the irradiated (30 Gy) and IFN-␥-stimulated (500 U/mL for 48 hours) or non-IFN-␥-stimulated Y-79 cells in the presence or absence of agonistic anti-CD3 mAb. For mAb blocking assay, purified mAb against B7H1 or control mouse IgG was added at a final concentration of 10 g/mL at the start of the assay. The cultures were incubated for 96 hours at 37°C in 5% CO 2 in air, pulsed with [
3 H] thymidine (1.0 Ci/10 L/well) during the last 18 hours of incubation, and then were harvested onto glass filters with an automated cell harvester. Radioactivity was assessed by liquid scintillation spectrometry (Tomtec, Orange, CT), and the amount was expressed as counts per minute.
Statistical Analysis and Reproducibility
Experiments were repeated at least twice and usually three times. Statistical analyses were performed by independent t-test. P Ͻ 0.05 was considered significant. Significance is denoted by an asterisk in the figures. 
RESULTS
Expression of Costimulatory Molecules, with or without IFN-␥, with Irradiation, or with IFN-␥ after Irradiation
The expression of costimulatory molecule mRNA by the human retinoblastoma cell line Y-79 was examined by RT-PCR under various conditions. To find the dose of recombinant IFN-␥ used in the assay, Y-79 cells were cultured in the presence of titrated amounts of IFN-␥ and MHC class I expression was analyzed by flow cytometry. More than 500 U/mL of IFN-␥ did not induce an obvious expression of MHC class I, consistent with a previous report. 7 IFN-␥ at 500 U/mL was therefore used in subsequent experiments for assessing the expression of costimulatory molecules in Y-79 cells.
CD40 and B7H2 mRNA were found to be expressed constitutively by Y-79 (Fig. 1) . CD40 mRNA expression increased on stimulation by IFN-␥ (500 U/mL) alone, irradiation (100 Gy) alone, or IFN-␥ (500 U/mL) after irradiation (100 Gy). MHC class II, DR, B7H1, and OX40L mRNA expression was induced after IFN-␥ stimulation. Y-79 stimulated with IFN-␥ or irradiation alone expressed very low or undetectable levels of CD80, and 4-1BBL. CD86 and B7DC expression was undetectable under all conditions. These results indicated that MHC class II, CD40, OX40L, B7H1, and B7H2 mRNA were either expressed constitutively or could be induced in the human retinoblastoma cell line Y-79.
The surface expression of various costimulatory molecules on the Y-79 cell line was analyzed by flow cytometry (Fig. 2) . The expression of MHC class I (A, B, C) molecules increased after IFN-␥ stimulation, which agreed with previous data on the Y-79 cell line. 7 Consistent with the mRNA expression results, the CD40 molecule was expressed constitutively on the surface of Y-79 cells, and was enhanced after stimulation with IFN-␥ alone, irradiation alone, or IFN-␥ after irradiation. In contrast, B7H2 expression did not increase after IFN-␥ stimulation. Moreover, only B7H1 expression was enhanced significantly after IFN-␥ stimulation, and this result was consistent with the mRNA expression data. Y-79 did not express surface molecules of MHC class II (DR, DP, DQ), CD80, CD86, CD70, 4-1BBL, and B7DC under any condition.
Effect of CD40 Ligation on MHC Class I and ICAM-1 Surface Molecules
Interaction between CD40 and CD40L activates antigen-presenting cells (APCs), leading to the upregulation of molecules involved in T-cell adhesion, antigen presentation, and activation. Examples of such molecules are ICAM-1, MHC class I and II molecules, and costimulatory molecules of the B7 family. 30 -32 In the analysis of cell surface antigen expression by (Fig. 3) . In contrast, after IFN-␥ priming, stimulation of CD40 by rhCD40L induced significant upregulation of MHC class I molecules compared with Y-79 primed with IFN-␥ alone or incubated with isotyped control Ig. Likewise, Y-79 stimulated with rhCD40L with or without IFN-␥ priming, showed twofold upregulation of ICAM-1 molecules compared with Y-79 primed with or without IFN-␥ alone, respectively, or incubated with isotyped control Ig. CD40 stimulation by rhCD40L had no effect on the surface expression of NCAM, LFA-2, MHC class II molecules, CD80, CD86, CD95, and CD95L (data not shown).
CD40 Mediation of In Vitro MCP-1 Production in IFN-␥-Treated Cells
CD40 ligation is known to induce the secretion of chemokines such as IL-8 and MCP-1 by a human malignant melanoma cell line and human cervical carcinoma cell line. 14, 33 This study analyzed the effects of CD40 ligation on chemokine secretion (MCP-1, MIP-1␣, MIP-1␤, RANTES, and IL-8) by the human retinoblastoma cell line Y-79. Y-79 cells were either untreated or primed with IFN-␥ (500 U/mL, 48 hours) and then incubated for 24 hours with rhCD40L, isotype control Ig, or medium alone. Y-79 cells primed with IFN-␥ (500 U/mL) 24 hours before CD40 stimulation resulted in significant release of MCP-1 into the culture supernatant (Fig. 4) . However, other chemokines including MIP-1␣, MIP-1␤, RANTES, and IL-8 were not detected in this culture condition. This confirms that rhCD40L-induced MCP-1 production from IFN-␥-treated Y-79 cells is mediated through the CD40/CD40L receptor interaction.
Effect of Blocking B7H1 on IFN-␥-Treated Y-79 -Mediated T-Cell Proliferation
As described earlier, B7H1 expression was detected on the cell surface of IFN-␥-treated and irradiated Y-79. Recent studies have demonstrated that B7H1 (also termed PDL1) and B7DC (also termed PDL2) can bind to PD-1, a member of the immunoglobulin (Ig) superfamily involved in lymphocyte proliferation and activation, and that PD-1 functions as an important negative regulator of the immune system. 34 -37 To determine whether B7H1 expressed on IFN-␥-treated Y-79 cells was functionally inhibited in T-cell proliferation, human CD3 ϩ T cell responses to agonistic anti-CD3 mAb (OKT3) were examined in the presence of Y-79 and antibodies blocking B7H1. We used this approach to test the hypothesis that B7H1 expressed on Y-79 suppresses the proliferative response of CD3 ϩ T cells. 
DISCUSSION
In this study, the expression of nine costimulatory molecules (CD80, CD86, CD40, CD70, B7H1, B7DC, B7H2, OX40L, and 4-1BBL) was investigated in the Y-79 cell line. The rationales for the study were as follows: (1) Costimulatory molecules are poorly expressed on the surface of tumor cells. 21 (2) Transfer of some costimulatory-molecule-coding genes into tumor cells leads to tumor rejection in vivo 38, 39 ; (3) No information is available on the expression and function of costimulatory molecules in human retinoblastoma. In the present study, CD40 and B7H2 proteins were expressed constitutively, and B7H1 The most important finding of the study is the constitutive expression of CD40 mRNA and protein in Y-79 cells. Furthermore, we demonstrated that CD40 expressed on human Y-79 cells is functional because CD40L-CD40 interaction acts synergistically with IFN-␥ to stimulate the cells to release the chemokine MCP-1, which attracts not only monocytes but also CD4-and CD8-positive memory T cells. 40 These results suggest that IFN-␥ produced by infiltrating activated T cells may sensitize human retinoblastoma cells to produce MCP-1 on contact with CD40L in the body. Further studies are needed to verify whether these phenomena occur in vivo. We also demonstrated that cross-linking of CD40 with its ligand on human Y-79 cells upregulates surface expression of MHC class I molecule and ICAM-1, which parallels observations made in immune cells such as APCs. 30, 31 However, in contrast to immune cells, CD40-mediated upregulation of MHC class II, CD80, or CD86 was not detected. It has been reported that the level of surface MHC class I and ICAM-1 expression on tumor cells is crucial for their recognition by specific cytotoxic T cells. 41, 42 Our findings that CD40 triggering upregulates MHC class I and ICAM-1 expression on human retinoblastoma may thus explain their enhanced susceptibility to specific cytotoxic T-cell-mediated killing. In human retinoblastoma showing no intense inflammatory reaction, therapeutic application of IFN-␥ may be considered a strong sensitizer for endogenous defense mechanisms via CD40L-CD40-mediated responses. Moreover, a trimeric recombinant form of soluble CD40L, recently tested in phase 1 studies on patients with lymphoma or solid tumor, showed limited toxicity, indicating the potential feasibility of this therapeutic approach in patients with retinoblastoma. 43 Many recent studies have indicated that B7H1 and B7DC are involved in negative regulation of immune responses through PD-1 expressed on activated T cells, B cells, and myeloid cells, 34, 36, 37 which is considered a candidate strategy by which tumor cells evade host immune surveillance. The present study is the first to demonstrate that anti-B7H1 mAb significantly enhances the proliferation of CD3 ϩ T cells costimulated with IFN-␥-stimulated Y-79. The regulatory mechanisms of B7H1 expression on tumor cells are not known. Inflammatory mediators are implicated based on findings of upregulated B7H1 expression on the surface of several tumor cell lines after exposure to IFN-␥. 19, 44 T cells or natural killer cells that infiltrate tumor tissue secrete many cytokines including IFN-␥ Therefore, one possible scenario is that the lymphocytes that initially infiltrate the retinoblastoma secrete IFN-␥, which upregulates B7H1 expression on the tumor cells. Consequently, the upregulated B7H1 on tumor cells may transfer negative signal to T cells via PD-1. The present findings suggest that the expression of B7H1 on Y-79 cells may contribute to negative regulation of immune responses against tumor-infiltrating lymphocytes in human retinoblastoma. Furthermore, negative response of T cells by the tumor cells through B7H1 may be expected to reduce T-cell cytolytic activity. However, a limitation of this study is that although we demonstrated negative regulation by T-cell proliferation, this phenomenon was not confirmed by direct killing ability, because the human T cells purified from PMBC did not induce sufficient cytolytic activity against Y-79 cells. Recent studies have reported that B7H1 blockade improves antitumor immunity and represents one approach for cancer immunotherapy. 44 -46 The blockade of B7H1 in human retinoblastoma could be another strategy to pursue future immunotherapy in human retinoblastoma.
In conclusion, we have demonstrated the expression of several costimulatory molecules on retinoblastoma cells under various conditions. These data could explain the enhanced immunogenicity of human retinoblastoma cells after inflammation and/or irradiation, and could lead to new immunotherapy protocols. Moreover, CD40 and B7H1 expressed on the tumor cells are functionally active. These results suggest that the expression of CD40 and B7H1 on Y-79 cells and the interactions of these molecules with their receptors expressed on infiltrated immune cells may contribute to the regulation of immune responses in the eye or at metastatic sites. Recently, regulation of costimulatory molecules has attracted attention as a possible strategy for exploring novel immunotherapy for tumors, and gene transfer of ocular melanoma cells with the CD80 vector results in the stimulation of tumor-specific T cells. 47 The present data may have important implications for human retinoblastoma immunotherapy in the future.
